The efficacy and response of switching from either donepezil or galantamine to rivastigmine transdermal patch in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial

The efficacy and response of switching from either donepezil or galantamine to rivastigmine transdermal patch in Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial - Multi-modal neuroimaging analysis of open-trial of switching from either donepezil or galantamine to rivastigmine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010556

Enrollment

Registered

2013-04-24

Start date

2013-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

The open-label, 12-month study evaluated the treatment effect and response of rivastigmine transdermal patch in Alzheimer patients who had previously failed to benefit from the treatment with either d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A diagnosis of probable AD according to the National Institute of Neurological and Communication Disorders and Stroke Alzheimer Disease and Related Disorders Association criteria, very mild to mild , moderate functional severity, reliable informed consent could be obtained from the patient and or his her relatives, the chief caregiver is the patients family ,the patients Mini Mental State Examination score was less than 11,poor response was defined as the score of MMSE or ADASJ cog over the half of a year during the treatment with either donepezil or galantamine

Exclusion criteria

Exclusion criteria: either previous history or now taking other choline inhibitors (rivastigmine) and memantine, taking antipsychotic or antidepressant medication ,there was a previous history of mental illness or substance abuse,either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings , the patient has pacemaker, other findings in terms with the aims of this study

Design outcomes

Primary

Measure	Time frame
multi-modal neuroimaging analysis 1 Structural neuroimaging analysis Brain MRI: voxel-based morphometry (VBM) diffusion tensor imaging (DTI) 2 Functional neuroimaging analysis single photon emission computed tomography (SPECT) near-infrared spectroscopy (NIRS)	—

Secondary

Measure	Time frame
1 Cognitive assessment Mini-Mental State Examination (MMSE) Clock drawing test The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog) Frontal assessment battery (FAB) 2 Behavior assessment Clinical assessment for spontaneity (CAS) Neuropsychiatry Inventory Questionnaire (NPI-Q) Quality of life-Alzheimer Disease (QOL-AD) Scale	—

Countries

Japan

Contacts

Public ContactShutaro Nakaaki

Keio University School of Medicine Department of Neuropsychiatry, Laboratory of Aging, Behavior and Cognition

hzi05510@nifty.com03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026